摘要
目的:探讨对结直肠癌患者进行FOLFOX4方案化疗时,5-FU稳态血药浓度和不良反应的相关性,为临床5-FU血药浓度监测和个体化用药提供依据。方法:38例结直肠癌患者接受标准FOLFOX4方案化疗,化疗的第2天采血并测定5-FU稳态血药浓度,观察化疗不良反应。结果:5-FU致骨髓抑制、口腔黏膜炎、腹泻的严重程度与其稳态血药浓度正相关,P<0.05。而恶心、呕吐和精神状况降低的严重程度和5-FU稳态血药浓度无相关性,P>0.05。结论:结直肠癌患者进行FOLFOX4方案化疗,5-FU稳态血药浓度与化疗毒副反应正相关,可作为不良反应的预测指标。中华肿瘤防治杂志,2011,18(2)
OBJECTIVE：To assess inter-patient vitiations of 5-FU steady-state concentration in FOLFOX4 regimen,and research the relationships between plasma concentration of 5-FU and adverse reactions in patients with colorectal cancer,in order to provide date for modulating dosage individually.METHODS： Thirty-eight patients with colorectal cancer were enrolled into the study to receive standard FOLFOX4 regimen chemotherapy.Blood samples were collected,and serum concentration of 5-FU at steady-state was measured on the second day after therapy.And the adverse events were surveyed and evaluated.RESULTS： Spearman correlation analysis showed that,5-FU plasma concentrations had positive relationships with the toxic degrees of oral mucositis,diarrhea and myelosurpression（P0.05）,wherase it had negative relationships with grades of nausea,vomitum and general state（P0.05）.CONCLUSION： The steady-state plasma concentrations of 5-FU is the index for predicting the severe degrees of toxicity in FOLFOX4 regimen for colorectal cancer patient.
出处
《中华肿瘤防治杂志》
CAS
2011年第2期134-136,共3页
Chinese Journal of Cancer Prevention and Treatment
